Table 1.
All patient characteristics at time of the first switch are listed in this table.
| Disease entity (n (%)) | ||
| CD | 60 (63%) | |
| UC | 35 (37%) | |
| Montreal classification | CD | UC |
| n (%) | A1: 7 (12%) | E1: 0 (0%) |
| A2: 45 (75%) | E2: 14 (40%) | |
| A3: 8 (13%) | E3: 21 (60%) | |
| L1: 13 (22%) | ||
| L2: 10 (17%) | ||
| L3: 37 (62%) | ||
| L4: 13 (22%) | ||
| B1: 16 (27%) | ||
| B2: 10 (17%) | ||
| B3: 34 (57%) | ||
| p: 18 (30%) | ||
| Gender | ||
| Female | 38 (40%) | |
| Male | 57 (60%) | |
| Age (years) | ||
| Median (range) | 39 (19–69) | |
| Disease duration (years) | ||
| Median (range) | 8 (1–48) | |
| Body mass-index (kg bw/m2) | ||
| Median (range) | 25.2 (16.5–50.1) | |
| Duration of previous infliximab treatment (months) | ||
| Median (range) | 33 (1–103) | |
| Clinical disease activity (n (%)) | ||
| Remission | 70 (74%) | |
| Mild | 18 (19%) | |
| Moderate | 7 (7%) | |
| Severe | 0 (0%) | |
bw, bodyweight; CD, Crohn’s disease; UC, ulcerative colitis.